Lupin Limited (Lupin) announced the launch of first generic version of Oracea® (Doxycycline Capsules, 40 mg), in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Doxy cycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Doxycycline Capsules had estimated annual sales of USD 128 million in the U.S. (IQVIA MAT February 2024).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,655 INR | +0.46% | +2.44% | +25.11% |
Apr. 24 | Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility | MT |
Apr. 22 | INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.11% | 9.05B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
-3.40% | 157B |
- Stock Market
- Equities
- LUPIN Stock
- News Lupin Limited
- Lupin Limited Announces the Launch of First Generic Version of Oracea® (Doxycycline Capsules, 40 Mg), in the United States